ES2192221T3 - Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso. - Google Patents

Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.

Info

Publication number
ES2192221T3
ES2192221T3 ES96500140T ES96500140T ES2192221T3 ES 2192221 T3 ES2192221 T3 ES 2192221T3 ES 96500140 T ES96500140 T ES 96500140T ES 96500140 T ES96500140 T ES 96500140T ES 2192221 T3 ES2192221 T3 ES 2192221T3
Authority
ES
Spain
Prior art keywords
overweight
obesity
treatment
group
estrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96500140T
Other languages
English (en)
Inventor
Maria Alemany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLEOYL ESTRONE DEVELOPMENTS S
Original Assignee
OLEOYL ESTRONE DEVELOPMENTS S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OLEOYL ESTRONE DEVELOPMENTS S filed Critical OLEOYL ESTRONE DEVELOPMENTS S
Application granted granted Critical
Publication of ES2192221T3 publication Critical patent/ES2192221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL ESTROGENO SE SELECCIONA DEL GRUPO QUE CONSTA DE ESTRONA, DIETILESTILBESTROL, ESTRIOL, ESTRADIOL Y ETINILESTRADIOL; EL ACIDO GRASO SE SELECCIONA DEL GRUPO QUE CONSTA DE ACIDOS OLEICOS, LINOLEICOS, LINOLENICOS, ESTEARICOS, PALMITICOS, PALMITOLEICOS Y ARAQUIDONICOS. IMITAN LA FUNCION DE MONOOLEATO DE ESTRONA, COMO UNA SEÑAL QUE INFORMA AL CEREBRO DEL TAMAÑO DE LA MASA DE TEJIDO GRASO. COMPOSICIONES PREFERIDAS PARA INYECCION INTRAVENOSA COMPRENDEN EL MONOESTER INCORPORADO EN UNA SUSPENSION LIPIDICA, PREPARADA A PARTIR DE LIPOPROTEINAS O A PARTIR DE COMPONENTES DE LIPOSOMA COMO ACEITE DE SOJA Y FOSFOLIPIDOS DE HUEVO. CUANDO SE ADMINISTRA A RATAS CON UN 15% DE TEJIDO ADIPOSO TOTAL, PRODUCEN REDUCCION DE PESO DE ALREDEDOR DEL 10%, MEDIANTE UN NUEVO E INESPERADO MECANISMO. SON UTILES PARA EL TRATAMIENTO DE OBESIDAD Y/O SOBREPESO EN MAMIFEROS, CON LAS VENTAJAS DE ALTA EFICACIA Y BAJA TOXICIDAD.
ES96500140T 1995-10-30 1996-10-28 Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso. Expired - Lifetime ES2192221T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9502101 1995-10-30

Publications (1)

Publication Number Publication Date
ES2192221T3 true ES2192221T3 (es) 2003-10-01

Family

ID=8291993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96500140T Expired - Lifetime ES2192221T3 (es) 1995-10-30 1996-10-28 Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.

Country Status (7)

Country Link
US (1) US5798348A (es)
EP (1) EP0771817B1 (es)
AT (1) ATE235505T1 (es)
DE (1) DE69626927T2 (es)
DK (1) DK0771817T3 (es)
ES (1) ES2192221T3 (es)
PT (1) PT771817E (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
AU4701299A (en) 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
US7025984B1 (en) 2000-06-26 2006-04-11 The Procter & Gamble Company Compositions and methods for body weight management
AU2005242170B2 (en) * 2000-06-26 2008-12-18 The Procter & Gamble Company Compositions and methods for body weight management
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
US6635015B2 (en) * 2001-04-20 2003-10-21 The Procter & Gamble Company Body weight management system
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US20040157816A1 (en) * 2002-08-26 2004-08-12 Girouard Michael P. Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
WO2003018529A1 (en) * 2001-08-24 2003-03-06 Girouard Michael P Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
WO2004045560A2 (en) * 2002-11-20 2004-06-03 Girouard Michael P Combination of monounsaturated fatty acids and estogen, and their use
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7528791B2 (en) * 2005-08-08 2009-05-05 Wistron Neweb Corporation Antenna structure having a feed element formed on an opposite surface of a substrate from a ground portion and a radiating element
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
WO2008147373A2 (en) * 2006-06-26 2008-12-04 Manhattan Pharmaceuticals, Inc. Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
ES2302449B1 (es) * 2006-10-30 2009-06-12 Oleoyl-Estrone Developments, S.L. Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
EP2085089A1 (en) * 2008-02-01 2009-08-05 KTB-Tumorforschungs GmbH Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265976A (en) * 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
GB531178A (en) * 1938-07-02 1940-12-31 Chem Ind Basel Manufacture of new esters of the oxy-stilbene series
JPH0610127B2 (ja) * 1985-02-09 1994-02-09 ライオン株式会社 養毛料
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control

Also Published As

Publication number Publication date
DE69626927T2 (de) 2003-11-20
US5798348A (en) 1998-08-25
DK0771817T3 (da) 2003-07-28
DE69626927D1 (de) 2003-04-30
ATE235505T1 (de) 2003-04-15
EP0771817A3 (en) 1999-04-14
EP0771817B1 (en) 2003-03-26
PT771817E (pt) 2003-06-30
EP0771817A2 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
ES2192221T3 (es) Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.
Bourre et al. High dietary fish oil alters the brain polyunsaturated fatty acid composition
Zampolli et al. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models
ES2074734T3 (es) Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
NO920067L (no) Foradditiv for droevtyggere
BR9803195A (pt) Produto alimentìcio à base de gordura,e, pasta de gordura amarela de espalhar.
DK1037666T3 (da) Metode til forøgelse af absorptionen og transporten af lipidopløselige forbindelser ved burg af strukturerede glycerider
FR2698269B1 (fr) Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
FI972431A7 (fi) Sytotoksisten T-lymfosyyttivasteiden induktio
BR0307101A (pt) Fracionamento de ésteres de fitosterol em óleo
JP2794433B2 (ja) 甘草疎水性フラボノイド製剤
KR960010832B1 (ko) 필수지방산 합성물(Essential Fatty Acid Compositins)
DE69625616T3 (de) Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
Crockett et al. A comparison of the coefficient of digestibility and the rate of absorption of several natural and artificial fats as influenced by melting point
Williams et al. Effects of dietary fat level on pantothenate depletion and liver fatty acid composition in the rat
ATE93722T1 (de) Omega-3-fettsaeurenhaltige fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung.
Larue et al. Effect of the removal of olfactory bulbs upon hyperphagia and obesity induced in rats by VMH lesion
US5484611A (en) Method of producing a fatty acid
IES940674A2 (en) "An edible fat blend containing fish oil"
KR910005872A (ko) 간염 예방 치료제
Leaf et al. Experimental studies on antiarrhythmic and antiseizure effects of polyunsaturated fatty acids in excitable tissues
ES2059827T3 (es) Emulsion para administracion parenteral.
WO2004045560A3 (en) Combination of monounsaturated fatty acids and estogen, and their use
RU95108891A (ru) Фармацевтическая эмульсия, содержащая биологически активные стероиды, способ получения эмульсии, применение эмульсии
KR920021151A (ko) 면역억제특성을 갖는 약제학적 조성물을 제조하기 위한 인지질 유도체의 용도